Bexxar (250 patients of Relapsed/refractory indolent FL andtransformed NHL, ORR 47%–68% repectively) [86]Bexxar (76 patients of Stage III or IV FL, ORR 95%) [87]Bexxar +Fludarabine (35 patients of Early stage FL, ORR 98%) [88]Bexxar vs tositumomab (78 patients of Relapsed or refractory NHL,ORR 55% vs 19%) [89–91]